Clinical trials and evidence
Clinical trials and real-world evidence support evidence-based medicine in healthcare, playing a pivotal role in validating and advancing medical treatments and interventions. Clinical trials assess the efficacy and safety of new drugs and therapies, with real-world evidence providing data to inform clinical and regulatory decisions based on empirical data.
Top Stories
-
News
09 Jun 2026
Will obesity drugs save Pfizer from its post-COVID slump?
With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline. Continue Reading
-
News
08 Jun 2026
Structure's GLP-1 obesity pill could compete with others on the market
Phase 2 data suggests Structure Therapeutics' GLP-1 pill, aleniglipron, could be a potential competitor in the growing market for oral obesity treatments, analysts say. Continue Reading
-
News
30 Aug 2021
J&J COVID-19 Vaccine Booster Elicits Strong Antibody Responses
Two Phase 1/2a clinical trials showed that Johnson & Johnson’s COVID-19 vaccine booster increased binding antibody responses in participants 18 to 55 years of age. Continue Reading
-
News
30 Aug 2021
Novartis Cancer Treatment Fails in Phase 3 Clinical Trial
Novartis cancer treatment Kymriah did not meet its primary endpoint of event-free survival compared to treatment with the standard-of-care in the Phase 3 clinical trial. Continue Reading
-
News
26 Aug 2021
FDA Accept Johnson & Johnson’s Expanded Indication for Xarelto
The indication for Johnson & Johnson’s Xarelto will now include patients following recent lower-extremity revascularization due to symptomatic peripheral artery disease. Continue Reading
-
News
26 Aug 2021
FDA Accepts Biologics License Application for BMS aGvHD Therapy
Bristol Myers Squibb’s aGvHD therapy is intended to prevent moderate to severe aGvHD in patients six years of age and older receiving unrelated donor hematopoietic stem cell transplant. Continue Reading
-
News
25 Aug 2021
AstraZeneca’s COVID-19 Antibody 77% Effective in Phase 3 Trial
Researchers reported no cases of severe coronavirus or coronavirus-related death in patients treated with the COVID-19 antibody combination, AZD7442. Continue Reading
-
News
24 Aug 2021
FDA Grants Accelerated Approval to GSK’s dMMR Antibody Drug
Other recent FDA approvals include Eli Lilly’s Jardiance to reduce the risk of cardiovascular death for adults with heart failure and Roche’s companion diagnostic test to identify solid tumors. Continue Reading
-
News
24 Aug 2021
CureVac’s Second COVID-19 Vaccine Elicits Improved Immune Response
In other COVID news, Pfizer and BioNTech submit Phase 1 COVID-19 vaccine data to FDA and Moderna revises supply agreement with Canada to provide 105M doses of its candidate. Continue Reading
-
News
23 Aug 2021
Novartis’ Diabetic Macular Edema Drug Successful in 2 Trials
In the global Phase 2 trials, Novartis’ diabetic macular edema drug elicited greater reductions versus aflibercept in CSFT and in the number of eyes with IRF/SRF. Continue Reading
-
News
23 Aug 2021
GoodRx, Boehringer Increase Affordable Drug Access for Patients
Patients with diabetes and COPD now have more affordable drug access to Boehringer Ingelheim’s portfolio of medications through the GoodRx platform. Continue Reading
-
News
19 Aug 2021
FDA Approves Abbott’s Atrial Fibrillation Device to Prevent Stroke
The device, Amplatzer Amulet Left Atrial Appendage Occluder, immediately closes the left atrial appendage to prevent blood clots and stroke in patients atrial fibrillation. Continue Reading
-
News
19 Aug 2021
Moderna Doses First Patient in Study of mRNA Therapeutic for MMA
The open-label landmark study will evaluate the safety and tolerability of up to five different dosing regimens of the mRNA therapeutic in patients with isolated methylmalonic acidemia. Continue Reading
-
News
18 Aug 2021
FDA Authorizes Thermo Fisher’s PCR-Based COVID-19 Test Kits
The COVID-19 test kits are designed with increased target redundancy to compensate for current mutations and emerging SARS-CoV-2 variants. Continue Reading
-
News
17 Aug 2021
WHO Launches Next Trial Phase to Test COVID-19 Drugs in Patients
The Solidarity PLUS trial will enroll hospitalized patients to test three potential COVID-19 drugs from Ipca, Novartis, and Johnson & Johnson. Continue Reading
-
News
16 Aug 2021
FDA OKs 3rd COVID-19 Vaccine Dose for the Immunocompromised
FDA determined that immunocompromised individuals may benefit from a third dose of the currently authorized COVID-19 vaccines as the US enters into a new wave of the pandemic. Continue Reading
-
News
11 Aug 2021
Kite, Appia Bio to Research Allogeneic Cell Therapies for Cancer
The companies will develop chimeric antigen receptor-engineered invariant natural killer cell therapies directed toward cancer. Continue Reading
-
News
10 Aug 2021
Moderna Doses First Patient in Study of Autoimmune mRNA Candidate
Moderna’s autoimmune mRNA candidate is a modified mRNA-encoded IL-2 and the first autoimmune candidate to enter the clinic. Continue Reading
-
News
10 Aug 2021
FDA Grants Fast Track to Moderna’s mRNA RSV Vaccine for Adults
Moderna’s RSV vaccine, mRNA-1345, generated a geometric mean rise in neutralizing antibodies relative to a baseline of at least 11-fold in a Phase 1 study. Continue Reading
-
News
09 Aug 2021
51% of Retail Pharmacy Customers Used Wellness Services in 2020-21
A new J.D. Powers study found that retail pharmacy customers’ most used wellness services in 2020 and 2021 included vaccinations and routine screenings. Continue Reading
-
News
05 Aug 2021
FDA Expands Authorization of Regeneron’s COVID-19 Antibody Cocktail
The expanded authorization allows the COVID-19 antibody cocktail to be used for post-exposure prophylaxis in individuals exposed to SARS-CoV-2 or who are at high risk of exposure. Continue Reading
-
News
04 Aug 2021
Eli Lilly, Kumquat to Discover Drug Candidates for Tumors
The companies will discover novel small molecule drug candidates that stimulate an enhanced tumor-specific immune response. Continue Reading
-
News
03 Aug 2021
AstraZeneca, Regeneron to Develop Drug Candidates to Treat Obesity
The companies will research and develop novel small molecule drug candidates directed against GPR75 to address obesity and related co-morbidities. Continue Reading
-
News
02 Aug 2021
Biogen’s Alzheimer’s Disease Drug Safe, Effective in Trial
The Alzheimer’s disease drug developed with Ionis Pharmaceuticals showed robust and dose-dependent lowering of tau protein in cerebrospinal fluid in patients. Continue Reading
-
News
29 Jul 2021
AbbVie, Calico Extend Partnership for Age-Related Disease Therapies
The collaboration will further the 20 early-stage programs already discovered that address age-related diseases and neurodegeneration. Continue Reading
-
News
28 Jul 2021
FDA Approves Merck’s Keytruda for Triple-Negative Breast Cancer
The FDA approval follows findings from a Phase 3 clinical trial showing that Keytruda combined with chemotherapy helped patients with triple-negative breast cancer. Continue Reading
-
News
26 Jul 2021
Pfizer, Arvinas to Develop Protein Degrader for Breast Cancer
The collaboration will combine Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics. Continue Reading
-
News
23 Jul 2021
High-Dose Buprenorphine Helped Untreated Opioid Use Disorder
A high dose of buprenorphine was safe and well-tolerated in patients with untreated opioid use disorder in the emergency department. Continue Reading
-
News
22 Jul 2021
Lilly Enters Collaboration for Phase 3 Trial of Alzheimer’s Drug
The placebo-controlled Phase 3 trial will evaluate whether treatment with Lilly’s Alzheimer’s drug can slow clinical progression of the disease in patients at risk of complications. Continue Reading
-
News
21 Jul 2021
Pfizer Completes Trial Enrollment for Lyme Disease Vaccine
The Phase 2 trial enrolled 625 adult and pediatric participants aged five to 65 years of age to support the acceleration of the Lyme disease vaccine’s pediatric program. Continue Reading
-
News
20 Jul 2021
J&J COVID-19 Vaccine Elicits Antibody Responses Against Variants
The COVID-19 vaccine elicited dual mechanisms of protection against the virus and variants of concern, including B.1.1.7, B.1.351, P.1, B.1.429, B.1.617.1, and the original Wuhan strain. Continue Reading
-
News
19 Jul 2021
Biogen, InnoCare Pharma Partner for Multiple Sclerosis Treatment
The multiple sclerosis treatment, orelabrutinib, is a Bruton’s tyrosine kinase inhibitor developed to treat cancer and in development for the treatment of autoimmune diseases. Continue Reading
-
News
19 Jul 2021
FDA Authorizes Ortho Clinical’s COVID-19 Antibody Test
The VITROS Anti-SARS-CoV- IgG Quantitative Test targets the S1 spike protein and is the first COVID-19antibody test to receive FDA emergency use authorization. Continue Reading
-
News
15 Jul 2021
Study Finds Major Medicare Overspending Generic Prescription Drugs
Medicare overspent by 13.2% in 2017 for generic prescription drugs, while Costco’s streamlined distribution system could have saved $2.6 billion on drugs. Continue Reading
-
News
14 Jul 2021
Moderna Doses First Patient in Study of Flu mRNA Vaccine Candidate
mRNA-1010 is Moderna’s first seasonal flu mRNA vaccine candidate to enter clinical trials and target lineages recommended by WHO to prevent the flu, including H1N1 and H3N2. Continue Reading
-
News
14 Jul 2021
Medicare Prescription Drug Prices Doubled Since 2005
The increase in prescription drug prices is linked to a 2005 change in how Medicare reimburses doctors and other providers for Part B medications, Duke researchers said. Continue Reading
-
News
13 Jul 2021
FDA Updates J&J COVID-19 Vaccine Label to Include Rare Disorder
An estimated 100 cases of Guillain-Barre syndrome have been reported among recipients of the Johnson & Johnson COVID-19 vaccine, of which 95% were deemed serious. Continue Reading
-
News
12 Jul 2021
FDA Seeks Investigation Over Approval of Alzheimer’s Drug, Aduhelm
FDA’s acting commissioner requested a federal investigation into interactions between Biogen and FDA staff during the approval process of its Alzheimer’s drug. Continue Reading
-
News
12 Jul 2021
Thermo Fisher, UC Davis Launch Center of Excellence for Metabolomics
The research collaboration will provide the metabolomics community with innovations, best practices, and standard operating procedures to support clinical studies and research. Continue Reading
-
News
08 Jul 2021
FDA Issues Complete Response Letter for Type 1 Diabetes Antibody
In the CRL, FDA stated that a single, low-dose pharmacokinetic/ pharmacodynamic bridging study in healthy volunteers failed to show pharmacokinetic comparability. Continue Reading
-
News
08 Jul 2021
Merck Gains FDA Approval for Expanded Indication of Keytruda
Keytruda is now approved to treat patients with recurrent or metastatic locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation. Continue Reading
-
News
07 Jul 2021
GSK, Alector to Develop Antibodies for Neurodegenerative Diseases
The antibodies AL001 and AL101 will elevate progranulin levels, a key regulator of immune activity in the brain with genetic links to various neurodegenerative diseases. Continue Reading
-
News
06 Jul 2021
AstraZeneca’s Antibody Favorable in RSV in Phase 2/3 Trial
AstraZeneca’s long-acting antibody, nirsevimab, was safe and tolerable compared to placebo when given to infants at high risk of RSV, chronic lung disease, or congenital heart disease. Continue Reading
-
News
05 Jul 2021
Pfizer Halts Distribution of Smoking Cessation Drug, Chantix
The smoking cessation drug is designed to partially activate the nicotinic receptor, but Pfizer paused distribution after finding carcinogens in the pills. Continue Reading
-
News
02 Jul 2021
Gilead Submits New Drug Application to FDA for HIV Treatment
In a Phase 2/3 trial, a higher proportion of patients who received the HIV treatment achieved a clinically meaningful viral load reduction compared to those who received a placebo. Continue Reading
-
News
01 Jul 2021
DTC Pharmaceutical Marketing Linked $324B in Medicare Drug Spending
Over two years, Medicare drug spending on DTC pharmaceutical marketing focused on three therapeutic categories: arthritis, diabetes, and depression. Continue Reading
-
News
01 Jul 2021
Higher Dose of Ozempic Further Advances Diabetes Care Management
Ozempic 2.0mg elicited a reduction of 2.2% in HbA1C, compared to a reduction of 1.9 % in patients who were treated with Ozempic 1.0mg, boosting diabetes care management. Continue Reading
-
News
29 Jun 2021
Kite’s T-Cell Therapy 60% Effective Against Large B-Cell Lymphoma
In a Phase 3 trial, Kite’s CAR T-cell therapy met the primary endpoint of event-free survival and the key secondary endpoint of objective response rate against large B-cell lymphoma. Continue Reading
-
News
29 Jun 2021
ViiV Healthcare, Halozyme to Develop Long-Acting HIV Treatment
ViiV Healthcare will have access to Halozyme Therapeutics drug delivery technology and recombinant human hyaluronidase PH20 enzyme to develop long-acting HIV treatment. Continue Reading
-
News
25 Jun 2021
Lilly’s Drug Receives Breakthrough Therapy for Alzheimer’s Disease
FDA granted the drug breakthrough therapy for Alzheimer’s disease based on clinical evidence from the company’s Phase 2 trial. Continue Reading
-
News
25 Jun 2021
FDA Gives EUA for Genentech's Actemra for COVID-19 Hospitalizations
Genentech's COVID-19 monoclonal antibody treatment is the latest therapy to receive emergency use authorization. Continue Reading
-
News
24 Jun 2021
Health Officials Say Myocarditis After COVID-19 Vaccination “Rare”
Although a small number of individuals have experienced myocarditis or pericarditis after their second COVID-19 vaccination, organizations such as HHS and the CDC say the side effect is rare. Continue Reading
-
News
23 Jun 2021
GoodRx Users Save an Average $30B on Prescription Drug Costs
In 2020, GoodRx users saved $30 billion on prescription drug costs and an average of 79% on retail drug prices for the 100 most purchased medications. Continue Reading
-
News
21 Jun 2021
Bristol Myers Squibb to Co-Develop Eisai’s Antibody Drug Conjugate
Bristol Myers Squibb will jointly develop and commercialize the antibody drug conjugate in Japan, China, US, Canada, Europe, and UK. Continue Reading
-
News
16 Jun 2021
Regeneron’s COVID-19 Antibody Cocktail Reduces Death by 20%
In the Phase 3 UK RECOVERY trial, 24% of patients in the COVID-19 antibody cocktail group died, compared to 30% of patients in the standard care group. Continue Reading
-
News
16 Jun 2021
FDA Guidance Addresses Patient Outcomes in Cancer Clinical Trials
The guidance addresses how to incorporate assessment of patient-reported outcomes in cancer clinical trials of drugs and biological products. Continue Reading
-
News
15 Jun 2021
Novavax COVID-19 Vaccine 100% Effective in Phase 3 Clinical Trial
Novavax’s COVID-19 vaccine-elicited 100% efficacy against moderate or severe coronavirus and 91% efficacy in high-risk populations. Continue Reading
-
News
09 Jun 2021
Breaking Down the Approval of Biogen’s Aducanumab
Earlier this week, FDA approved Biogen’s drug for Alzheimer’s disease, aducanumab, after longstanding debate over the drug’s efficacy. Continue Reading
-
News
07 Jun 2021
FDA Greenlights Biogen Alzheimer’s Drug Aducanumab Amidst Debate
The OK comes after serious pressure from Alzheimer’s patients and their advocates to get another drug for the disease on the market. Continue Reading
-
News
04 Jun 2021
EU Approves AstraZeneca’s Non-Small Cell Lung Cancer Drug
In a Phase 3 clinical trial, AstraZeneca’s non-small cell lung cancer drug reduced the risk of disease recurrence or death by 83% in patients with Stage II and IIIA disease. Continue Reading
-
News
26 May 2021
J&J’s Biologic Therapy Stelara Helps Crohn’s, Ulcerative Colitis
Johnson & Johnson’s SEAVUE study found that 64.9% of patients treated with the biologic therapy, Stelara achieved clinical remission at one year. Continue Reading
-
News
25 May 2021
Moderna’s mRNA COVID-19 Vaccine 100% Effective in Adolescents
The TeenCOVE study found that Moderna’s COVID-19 vaccine was 93% effective in seronegative participants 14 days after the first dose and 100% effective 14 days after the second dose. Continue Reading
-
News
25 May 2021
FDA Approves Janssen’s Targeted Non-Small Cell Lung Cancer Therapy
The therapy from Janssen elicited a response rate of 40% in a study of 81 patients with non-small cell lung cancer and EGFR exon 20 insertion mutations. Continue Reading
-
News
24 May 2021
GSK-Medicago COVID-19 Vaccine Elicits High Antibody Responses
After the second dose of the COVID-19 vaccine, both age cohorts responded with neutralizing antibody titers that were 10 times higher than those in patients recovering from coronavirus. Continue Reading
-
News
24 May 2021
Thermo Fisher, UCSF Boost Manufacturing of Cell-Based Therapies
Thermo Fisher Scientific will build and operate a center on UCSF’s Mission Bay Campus to discover, manufacture, and distribute cell-based therapies. Continue Reading
-
News
21 May 2021
GSK, Sanofi COVID-19 Vaccine Elicits Strong Antibody Response
The COVID-19 vaccine candidate elicited a 95% to 100% seroconversion following a second injection in all age groups and across all doses in a Phase 2 clinical trial. Continue Reading
-
News
19 May 2021
Biogen’s XLRP Gene Therapy Fails in Phase 2/3 Clinical Trial
The gene therapy did not meet the primary endpoint of statistically significant improvement in the proportion of treated study eyes with ≥7 dB improvement from baseline. Continue Reading
-
News
18 May 2021
Merck’s Keytruda Helps Patients with High-Risk Breast Cancer
A Phase 3 clinical trial found that Keytruda met its primary endpoint of event-free survival when compared with chemotherapy alone in patients with high-risk triple-negative breast cancer. Continue Reading
-
News
17 May 2021
Top mRNA COVID-19 Vaccines 94% Effective, New CDC Data Shows
The real-word data comes from a CDC study of healthcare personnel who received two doses of either Pfizer’s or Moderna’s mRNA COVID-19 vaccine. Continue Reading
-
News
13 May 2021
Eli Lilly Taps saRNA Research Tech from MiNA for Drug Discovery
The companies will leverage MiNA’s small activating RNA (saRNA) research technology platform to research up to five novel drug candidates that address specific therapeutic areas. Continue Reading
-
News
12 May 2021
Eli Lilly Takes on Digital Diabetes Care Management
Along with DexCom, Glooko Inc, myDiabby Healthcare, and Roche, Eli Lilly will streamline diabetes care management through automated data collection for insulin dose tracking. Continue Reading
-
News
11 May 2021
Pfizer COVID-19 Vaccine Can be Used in Adolescents, FDA Says
FDA has amended the original emergency use authorization for Pfizer COVID-19 vaccine to include adolescents 12 through 15 years of age. Continue Reading
-
News
10 May 2021
NHS Rolls Out 3D Imaging Technology for Heart Disease Diagnosis
The 3D imaging technology turns a regular CT scan of the heart into a 3D image, which allows doctors to diagnose life-threatening coronary heart disease in 20 minutes. Continue Reading
-
News
06 May 2021
MedRhythm Begins Trial to Study Digital Therapeutics for Stroke
In partnership with UMass Memorial Healthcare, the trial studying digital therapeutics for stroke will be split in two phases, one in the hospital setting and one post-discharge. Continue Reading
-
News
04 May 2021
FDA Greenlights AstraZeneca’s Farxiga for Chronic Kidney Disease
In a study, 197 of the 2,152 patients who received AstraZeneca’s Farxiga had at least one composite endpoint event compared to 312 of the 2,152 patients who received a placebo. Continue Reading
-
News
04 May 2021
Moderna Increases Global 2022 COVID-19 Vaccine Capacity to 3B
The global COVID-19 vaccine capacity will be dependent upon the mix between Moderna’s authorized vaccine and lower doses of its variant booster candidates and pediatric vaccines. Continue Reading
-
News
28 Apr 2021
Few Drugs Make Half of Medicare Prescription Drug Spending
A small number of drugs accounted for a large share of Medicare prescription drug spending in 2019, and those drugs generally didn’t have generic or biosimilar competitors. Continue Reading
-
News
27 Apr 2021
Early COVID-19 Treatments Elicited No Real Benefits in Patients
Researchers found that there was no significant benefit of using COVID-19 treatments hydroxychloroquine and lopinavir-ritonavir in hospitalized patients. Continue Reading
-
News
26 Apr 2021
COVID-19 Mortality Dropped as Drug Therapies Emerged
A new study suggests that drug therapies for COVID-19 as well as more clinical experience treating the virus may have contributed to lower COVID-19 mortality rates. Continue Reading
-
News
21 Apr 2021
FDA Rescinds EUA for Eli Lilly’s Monoclonal COVID-19 Antibody
The agency determined that the known benefits of the COVID-19 antibody alone no longer outweigh the known and potential risks for its authorized use. Continue Reading
-
News
21 Apr 2021
FDA Approves Opdivo as First Immunotherapy for Gastric Cancer
A randomized trial found that the median survival for patients treated with the immunotherapy lived over two months longer than those who received chemotherapy alone. Continue Reading
-
News
19 Apr 2021
Trial Updates from Moderna’s mRNA, RSV Vaccine Candidates
Moderna announced updates from a Phase 1 study of its RSV vaccine candidate, as well as a Phase 2 study of its mRNA vaccine candidate. Continue Reading
-
News
16 Apr 2021
China Approves AstraZeneca’s Non-Small Cell Lung Cancer Drug
AstraZeneca’s prescription drug, Tagrisso, is the only targeted medicine to show efficacy in the treatment of early-stage non-small cell lung cancer in a global trial. Continue Reading
-
News
15 Apr 2021
Gilead Stops Phase 3 Remdesivir Trial in COVID-19 Patients
Gilead no longer believes that developing the COVID-19 treatment as a multiple-day injection in a healthcare setting addresses the unmet need for non-hospitalized patients. Continue Reading
-
News
14 Apr 2021
Medical AI Device Evaluation Process Could Mask Vulnerabilities
A majority of data test sets from FDA-approved medical AI devices were collected and evaluated before device deployment rather than concurrently, which can mask vulnerabilities. Continue Reading
-
News
14 Apr 2021
FDA Approves Marketing of AI Medical Device to Detect Colon Cancer
The medical device, GI Genius, uses AI to highlight portions of the colon where there may be a potential lesion for real-time detection during a colonoscopy. Continue Reading
-
News
09 Apr 2021
Data Reveals High Vaccine Efficacy for Moderna, Pfizer Doses
New data reveals high vaccine efficacy for both the Moderna and Pfizer-BioNTech vaccines, while clinical trial results hamper baricitinib use for COVID patients. Continue Reading
-
News
05 Apr 2021
NIH Launches COVID Variant Trial; Pfizer Releases New Data
In other COVID-19 vaccine news, J&J is on track to meet its vaccine distribution goal and GSK will help Novavax manufacture its vaccine. Continue Reading
-
News
02 Apr 2021
TCR2 Establishes Cell Therapy Manufacturing Facility in MD
TCR2 aims to treat several thousand cancer patients annually through its newly established cell therapy manufacturing facility. Continue Reading
-
News
01 Apr 2021
FDA Requests More Data from Merck on Keytruda for Breast Cancer
FDA officials stated that further data is needed from Merck’s Phase 3 trial of its monoclonal antibody, Keytruda, before a regulatory decision is made. Continue Reading
-
News
31 Mar 2021
Pfizer-BioNTech COVID-19 Vaccine 100% Effective in Adolescents
The Phase 3 trial enrolled 2,260 adolescents aged 12 to 15 years old and found that the overall results exceeded those recorded earlier in vaccinated participants 16 to 25 years of age. Continue Reading
-
News
31 Mar 2021
Real-World Evidence Confirms Efficiency of mRNA COVID-19 Vaccines
A CDC study used real-world evidence to find that both Pfizer and Moderna’s COVID-19 vaccines reduced risk of infection 90% two or more weeks after the second dose. Continue Reading
-
News
30 Mar 2021
Children Produce More COVID-19 Antibodies, Study Finds
A cross-sectional study found that younger children exhibited notably higher COVID-19 antibody production than adolescents and young adults. Continue Reading
-
News
30 Mar 2021
Moderna Studies COVID-19 Vaccine Candidate in Pediatric Population
The Phase 2/3 study will evaluate Moderna’s COVID-19 vaccine candidate in 6,750 healthy pediatric participants less than 12 years of age. Continue Reading
-
News
26 Mar 2021
COVID-19 Antigen Tests Prove More Accurate in Symptomatic Patients
While the COVID-19 antigen tests correctly identified 72%of people who were infected with the virus, the test only correctly identified 58% of asymptomatic patients. Continue Reading
-
News
25 Mar 2021
AstraZeneca COVID-19 Vaccine 76% Effective in Phase 3 Trial
The COVID-19 vaccine showed comparable efficacy results across ethnicity and age, with 85% efficacy in participants aged 65 years and over. Continue Reading
-
News
24 Mar 2021
Eli Lilly’s COVID-19 Antibody Reduces Hospitalizations by 87%
The second positive Phase 3 trial readout for the COVID-19 antibody combination supports the use of bamlanivimab at 700 mg and etesevimab at 1400 mg. Continue Reading
-
News
24 Mar 2021
COVID-19 Hospitalizations Spark Overuse of Antibiotic Concerns
A Pew Charitable Trusts study found that 52% of COVID-19 hospitalizations resulted in antibiotic prescribing even though just 20% of those admitted were diagnosed with infection. Continue Reading
-
News
23 Mar 2021
GSK COVID-19 Antibody Elicits 85% Drop in Hospitalizations, Deaths
A Phase 3 trial found an 85% reduction in hospitalization or death in 583 non-hospitalized patients who received the COVID-19 antibody compared to a placebo. Continue Reading
-
News
22 Mar 2021
Real-World Evidence Confirms Pfizer COVID-19 Vaccine Effectiveness
Real-world evidence gathered by the Israel Ministry of Health found lower coronavirus disease rates in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 vaccine. Continue Reading
-
News
19 Mar 2021
UK and EU Reaffirm Safety of AstraZeneca’s COVID-19 Vaccine
MHRA and EMA both stated that AstraZeneca’s COVID-19 vaccine continues to outweigh the risks and that vaccinations should continue. Continue Reading
-
News
19 Mar 2021
Eli Lilly, Biolojic to Develop Antibody Therapies for Diabetes
The partnership will leverage Biolojic’s artificial intelligence-based platform to discover and develop multi-specific antibody therapies for the treatment of diabetes. Continue Reading